213 related articles for article (PubMed ID: 27450784)
21. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease.
Guo B; Tan Q; Guo D; Shi Z; Zhang C; Guo W
J Vasc Surg; 2014 Oct; 60(4):993-1001. PubMed ID: 24877854
[TBL] [Abstract][Full Text] [Related]
22. Paraoxonase 1 (Q192R) gene polymorphism, coronary heart disease and the risk of a new acute coronary event.
Martínez-Quintana E; Rodríguez-González F; Medina-Gil JM; Garay-Sánchez P; Tugores A
Clin Investig Arterioscler; 2017; 29(1):1-6. PubMed ID: 27863895
[TBL] [Abstract][Full Text] [Related]
23. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY
JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435
[TBL] [Abstract][Full Text] [Related]
24. Association between Paraoxonase 1 (PON1) Polymorphisms and the Risk of Acute Coronary Syndrome in a North African Population.
Bounafaa A; Berrougui H; Ghalim N; Nasser B; Bagri A; Moujahid A; Ikhlef S; Camponova P; Yamoul N; Simo OK; Essamadi A; Khalil A
PLoS One; 2015; 10(8):e0133719. PubMed ID: 26241956
[TBL] [Abstract][Full Text] [Related]
25. Positive clinical response to clopidogrel is independent of paraoxonase 1 Q192R and CYP2C19 genetic variants.
Martínez-Quintana E; Medina-Gil JM; Rodríguez-González F; Garay-Sánchez P; Limiñana JM; Saavedra P; Tugores A
J Clin Pharmacol; 2014 Aug; 54(8):843-9. PubMed ID: 24504666
[TBL] [Abstract][Full Text] [Related]
26. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
Sibbing D; Koch W; Gebhard D; Schuster T; Braun S; Stegherr J; Morath T; Schömig A; von Beckerath N; Kastrati A
Circulation; 2010 Feb; 121(4):512-8. PubMed ID: 20083681
[TBL] [Abstract][Full Text] [Related]
27. Impacts of
Zhang M; Wang J; Zhang Y; Zhang P; Jia Z; Ren M; Jia X; Ma L; Gao M; Hou Y
Drug Des Devel Ther; 2020; 14():669-676. PubMed ID: 32109992
[TBL] [Abstract][Full Text] [Related]
28. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
[TBL] [Abstract][Full Text] [Related]
29. Human serum paraoxonase gene polymorphisms, Q192R and L55M, are not associated with the risk of cerebral infarction in Chinese Han population.
Huang Q; Liu YH; Yang QD; Xiao B; Ge L; Zhang N; Xia J; Zhang L; Liu ZJ
Neurol Res; 2006 Jul; 28(5):549-54. PubMed ID: 16808888
[TBL] [Abstract][Full Text] [Related]
30. Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention.
Saiz-Rodríguez M; Belmonte C; Caniego JL; Koller D; Zubiaur P; Bárcena E; Romero-Palacián D; Eugene AR; Ochoa D; Abad-Santos F
Clin Ther; 2019 Jun; 41(6):1199-1212.e2. PubMed ID: 31128980
[TBL] [Abstract][Full Text] [Related]
31. Distribution of CYP2C19, ABCB1 and PON1 polymorphisms in Chinese Han, Hui, Uygur and Kazak patients with coronary atherosclerotic heart disease.
Ma L; Yuan Y; Li J; Yu C; Zhao J
Int J Immunogenet; 2020 Dec; 47(6):539-545. PubMed ID: 32862511
[TBL] [Abstract][Full Text] [Related]
32. PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes.
Mega JL; Close SL; Wiviott SD; Man M; Duvvuru S; Walker JR; Sundseth SS; Collet JP; Delaney JT; Hulot JS; Murphy SA; Paré G; Price MJ; Sibbing D; Simon T; Trenk D; Antman EM; Sabatine MS
J Thromb Thrombolysis; 2016 Apr; 41(3):374-83. PubMed ID: 26573179
[TBL] [Abstract][Full Text] [Related]
33. Impact of CYP2C19 polymorphism on clinical outcome following coronary stenting is more important in non-diabetic than diabetic patients.
Mizobe M; Hokimoto S; Akasaka T; Arima Y; Kaikita K; Morita K; Miyazaki H; Oniki K; Nakagawa K; Ogawa H
Thromb Res; 2014 Jul; 134(1):72-7. PubMed ID: 24821368
[TBL] [Abstract][Full Text] [Related]
34. Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
Braun OÖ; Angiolillo DJ; Ferreiro JL; Jakubowski JA; Winters KJ; Effron MB; Duvvuru S; Costigan TM; Sundseth S; Walker JR; Saucedo JF; Kleiman NS; Varenhorst C
Thromb Haemost; 2013 Dec; 110(6):1223-31. PubMed ID: 24009042
[TBL] [Abstract][Full Text] [Related]
35. Relationship between cytochrome P450 2C19*2 polymorphism and stent thrombosis following percutaneous coronary intervention in Chinese patients receiving clopidogrel.
Luo Y; Zhao YT; Verdo A; Qi WG; Zhang DF; Hu B
J Int Med Res; 2011; 39(5):2012-9. PubMed ID: 22118006
[TBL] [Abstract][Full Text] [Related]
36. CYP2C19 genotyping combined with on-clopidogrel platelet reactivity in predicting major adverse cardiovascular events in Chinese patients with percutaneous coronary intervention.
Tang XF; Han YL; Zhang JH; Wang J; Yao Y; He C; Xu B; Gao Z; Qiao SB; Chen J; Wu Y; Chen JL; Gao RL; Yang YJ; Yuan JQ
Thromb Res; 2016 Nov; 147():108-114. PubMed ID: 27728892
[TBL] [Abstract][Full Text] [Related]
37. Characterization of patients with angioscopically-detected in-stent mural thrombi – genetics of clopidogrel responsiveness and generations of drug-eluting stents.
Ichikawa M; Takei Y; Hamasaki T; Kijima Y
Circ J; 2015; 79(1):85-90. PubMed ID: 25744629
[TBL] [Abstract][Full Text] [Related]
38. Association of PON1 genotype and haplotype with susceptibility to coronary artery disease and clinical outcomes in dual antiplatelet-treated Han Chinese patients.
Kang YH; Lao HY; Wu H; Lai WH; Li XX; Yu XY; Chen JY; Zhong SL
Eur J Clin Pharmacol; 2013 Aug; 69(8):1511-9. PubMed ID: 23608957
[TBL] [Abstract][Full Text] [Related]
39. [Influence of CYP2C19 gene polymorphisms on the efficacy of clopidogrel treatment for the prevention of ischemic stroke following coronary stent implantation].
Li G; Chen J; Xu Z; Wang Y; Ding N; Peng L; Zhang C; Shao Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2017 Dec; 34(6):839-843. PubMed ID: 29188612
[TBL] [Abstract][Full Text] [Related]
40. Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndrome.
Cuisset T; Quilici J; Cohen W; Fourcade L; Saut N; Pankert M; Gaborit B; Carrieri P; Morange PE; Bonnet JL; Alessi MC
Am J Cardiol; 2011 Sep; 108(6):760-5. PubMed ID: 21803320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
